PD-L1 expression – using immunohistochemistry with DAKO 22C3 antibody – was observed in ≥50% of tumor cells for 10 patients, six of whom had a response to pembrolizumab; only three of the 27 patients with PD-L1 expression by tumor cells <50% had a response. Here, CD274 is linked to neoplasm.